Loading
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Latest quote
$3.46
$0.00 · 0.00%
After-hours
$3.47
+$0.01 · +0.29%
Sep 15, 5:05 PM ET
Regular session · ET · Market data may be delayed.
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Day range
Current $3.46
52-week range
Current $3.46
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
52
Mixed
Risk
63
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Day range
Current $3.46
52-week range
Current $3.46
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.76M USD | 6.08M USD | 3.86M USD | 6.91M USD | 6.33M USD |
| Selling, general, and administrative | 12.01M USD | 9.31M USD | 13.2M USD | 15.98M USD | 23.37M USD |
| Operating expenses | 15.3M USD | 16.14M USD | 23.79M USD | 27.43M USD | 33.74M USD |
| Interest income | 236.08K USD | 572.89K USD | 786.36K USD | 367.74K USD | 1.29K USD |
| Interest expense | 618.64K USD | 47.58K USD | 299 USD | 48.82K USD | 69.4K USD |
| Depreciation and amortization | 545.78K USD | 490.57K USD | 2.51M USD | 4.54M USD | 4.05M USD |
| Operating income | −15.3M USD | −16.14M USD | −23.79M USD | −27.43M USD | −33.74M USD |
| Net income | −26.18M USD | −14.2M USD | −17.9M USD | −23.61M USD | −35.29M USD |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 15, 2024 | 1:65 | — | — |
Stock split | Oct 16, 2019 | 1:201 | — | — |
Effective Aug 15, 2024
1:65
Effective Oct 16, 2019
1:201
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
